All In MedTech

FDA Clearance Tracker · P200035-S002

OrganOx metra® System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 27, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 27, 2022

Approved

Time to decision

67 days

Received Mar 21, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P200035-S002
Device name
OrganOx metra® System
Applicant location
Oxford
Received
Mar 21, 2022
Decided
May 27, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P200035

Device type

Device class
Class III

Every decision under product code QQK

FDA's approval statement

As written in FDA's record.

Approval for the OrganOx metra® New Enrollment PAS. The OrganOx metra® New Enrollment PAS is a multi-center, single-arm, unblinded post-approval study designed to compare recipients of PAS NMP livers versus IDE SCS livers with respect to adverse biliary-related events. Recruitment will take place at a minimum of 10 sites which are UNOS member liver transplant centers.

Source documents

Other decisions for Organox Limited

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.